Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of Postal Ballot/E-voting
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma has announced a postal ballot and e-voting process for shareholders covering three items: (1) ratification of ₹31.26 lakh remuneration payable to M/s. Narasimha Murthy & Co. as Cost Auditor for FY2025-26; (2) amendment to the Main Objects clause of the Memorandum of Association to add a new business activity covering captive and renewable power generation (solar, hydro, wind, nuclear, and other non-conventional sources), including transmission, distribution, and sale of surplus power; (3) re-appointment of Dr. Pawan Goenka (DIN: 00254502) as an Independent Director for a second 5-year term from 21 May 2026 to 20 May 2031, including continuation past the age of 75. The e-voting window runs from 19 March 2026 (9:00 AM) to 17 April 2026 (5:00 PM), with results to be announced by 20 April 2026. Items 2 and 3 require Special Resolutions, while Item 1 is an Ordinary Resolution.
Routine governance exercise with no immediate material effect on share price. The MOA amendment signals Sun Pharma's intent to set up captive and renewable energy projects, which could gradually lower long-term power costs and align with its ESG roadmap. Continuity of Dr. Pawan Goenka (Padma Shri awardee, ex-M&M MD, current IN-SPACe Chairperson) as Lead Independent Director provides stability in board oversight.